Publications by authors named "Eric Massana"

Claim this Profile
E
Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage).
Richard B Warren, Marjolein de Bruin-Weller, Athanasios Tsianakas, Abdallah Khemis, Jacek C Szepietowski, Eric Massana

Br J Dermatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol.
Matthias Augustin, Anthony Bewley, Marie-Charlotte Brüggen, Marjolein S de Bruin-Weller, Khaled Ezzedine, Eric Massana

BMJ Open· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study.
Ulrich Mrowietz, Rachel Sommer, Sascha Gerdes, Ziad Reguiai, Wolfgang Weger, Eric Massana

Psoriasis (Auckl)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study).
Matthias Augustin, Rachel Sommer, Esteban Daudén, Philip Laws, Elke de Jong, Eric Massana

BMJ Open· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and tolerability of once-daily abediterol in patients with stable, persistent asthma: a Phase II, randomized, 7-day, crossover study.
Jutta Beier, Rainard Fuhr, Beatriz Seoane, Eric Massana, Gonzalo de Miquel

Pharmacol Res Perspect· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD.
Jutta Beier, Helena Pujol, Beatriz Seoane, Eulalia Jimenez, Carol Astbury, Eric Massana

BMC Pulm Med· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long-acting Β2 -agonist.
Wolfgang Timmer, Eric Massana, Eulalia Jimenez, Beatriz Seoane, Gonzalo de Miquel

J Clin Pharmacol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study.
Dave Singh, Helena Pujol, Anna Ribera, Beatriz Seoane, Eric Massana

BMC Pulm Med· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis